173 related articles for article (PubMed ID: 12937077)
1. Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis.
Salama HH; Hong J; Zang YC; El-Mongui A; Zhang J
Brain; 2003 Dec; 126(Pt 12):2638-47. PubMed ID: 12937077
[TBL] [Abstract][Full Text] [Related]
2. Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing-remitting multiple sclerosis patients.
Berthelot L; Miqueu P; Pettré S; Guillet M; Moynard J; Wiertlewski S; Lefrère F; Brouard S; Soulillou JP; Laplaud DA
Clin Immunol; 2010 Apr; 135(1):33-42. PubMed ID: 20116333
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy.
Karussis D; Teitelbaum D; Sicsic C; Brenner T;
J Neuroimmunol; 2010 Mar; 220(1-2):125-30. PubMed ID: 20153903
[TBL] [Abstract][Full Text] [Related]
4. Glatiramer acetate-specific human CD8(+) T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment.
Dressel A; Vogelgesang A; Brinkmeier H; Mäder M; Weber F
J Neuroimmunol; 2006 Dec; 181(1-2):133-40. PubMed ID: 17084909
[TBL] [Abstract][Full Text] [Related]
5. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins.
Sarchielli P; Zaffaroni M; Floridi A; Greco L; Candeliere A; Mattioni A; Tenaglia S; Di Filippo M; Calabresi P
Mult Scler; 2007 Apr; 13(3):313-31. PubMed ID: 17439900
[TBL] [Abstract][Full Text] [Related]
6. Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid.
Hestvik AL; Skorstad G; Price DA; Vartdal F; Holmoy T
Mult Scler; 2008 Jul; 14(6):749-58. PubMed ID: 18611988
[TBL] [Abstract][Full Text] [Related]
7. Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis.
Valenzuela RM; Costello K; Chen M; Said A; Johnson KP; Dhib-Jalbut S
Mult Scler; 2007 Jul; 13(6):754-62. PubMed ID: 17613604
[TBL] [Abstract][Full Text] [Related]
8. Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis. A pilot study.
Farina C; Wagenpfeil S; Hohlfeld R
J Neurol; 2002 Nov; 249(11):1587-92. PubMed ID: 12420101
[TBL] [Abstract][Full Text] [Related]
9. Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis.
Thouvenot E; Hillaire-Buys D; Bos-Thompson MA; Rigau V; Durand L; Guillot B; Camu W
Mult Scler; 2007 Aug; 13(7):941-4. PubMed ID: 17881403
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients.
Kim HJ; Biernacki K; Prat A; Antel JP; Bar-Or A
Clin Immunol; 2004 Apr; 111(1):38-46. PubMed ID: 15093550
[TBL] [Abstract][Full Text] [Related]
11. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role.
Liblau R
J Neurol Sci; 2009 Dec; 287 Suppl 1():S17-23. PubMed ID: 20106343
[TBL] [Abstract][Full Text] [Related]
12. Glatiramer acetate.
Comi G; Moiola L
Neurologia; 2002 May; 17(5):244-58. PubMed ID: 12031214
[TBL] [Abstract][Full Text] [Related]
13. Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients.
Mosley RL; Gordon PH; Hasiak CM; Van Wetering FJ; Mitsumoto H; Gendelman HE
Amyotroph Lateral Scler; 2007 Aug; 8(4):235-42. PubMed ID: 17653922
[TBL] [Abstract][Full Text] [Related]
14. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
[TBL] [Abstract][Full Text] [Related]
15. During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4.
Basile E; Gibbs E; Aziz T; Oger J
J Neuroimmunol; 2006 Aug; 177(1-2):161-6. PubMed ID: 16765453
[TBL] [Abstract][Full Text] [Related]
16. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor.
Ziemssen T; Kümpfel T; Klinkert WE; Neuhaus O; Hohlfeld R
Brain; 2002 Nov; 125(Pt 11):2381-91. PubMed ID: 12390966
[TBL] [Abstract][Full Text] [Related]
17. Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis.
Sanna A; Fois ML; Arru G; Huang YM; Link H; Pugliatti M; Rosati G; Sotgiu S
Clin Exp Immunol; 2006 Feb; 143(2):357-62. PubMed ID: 16412061
[TBL] [Abstract][Full Text] [Related]
18. [Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis].
Oreja-Guevara C; Bermejo PE; Miralles A; Gabaldón L; Aguilar MJ; Díez-Tejedor E
Neurologia; 2009 Sep; 24(7):435-8. PubMed ID: 19921551
[TBL] [Abstract][Full Text] [Related]
19. Glatiramer acetate-specific antibody titres in patients with relapsing / remitting multiple sclerosis and in experimental autoimmune encephalomyelitis.
Bomprezzi R; Schaefer R; Reese V; Misra A; Vollmer TL; Kala M
Scand J Immunol; 2011 Sep; 74(3):219-226. PubMed ID: 21615449
[TBL] [Abstract][Full Text] [Related]
20. Patterns of TH1/TH2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate.
Tumani H; Kassubek J; Hijazi M; Lehmensiek V; Unrath A; Süssmuth S; Lauda F; Kapfer T; Fang L; Senel M; Brettschneider J
Eur Neurol; 2011; 65(3):164-9. PubMed ID: 21372576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
